Riskpilot← Back to searchSign inGet full accessVELOXIS PHARMACEUTICALS A/S
A/SActiveCVR 26527767Gdanskgade 18Research and experimental development on natural sciences and engineering · NACE 7210Est. 20021 employeeswww.veloxis.com
Revenue 2025
—
EBITDA margin
—
-91% vs 2024
Equity ratio
98.6%
Financial strength
Net profit 2025
DKK -644K
+95% vs 2024
| Revenue | — | — |
| EBITDA | DKK -589K | -91% |
| Net profit | DKK -644K | +95% |
| Total assets | DKK 89,9M | +2603% |
| Equity | DKK 88,6M | +945% |
| Employees | 1 | — |
Legal name
VELOXIS PHARMACEUTICALS A/S
CVR number
26527767
Legal form
Aktieselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. marts 2002
Share capital
DKK 686.400.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af et medlem af bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udøve medicinsk forskning, produktion og salg af sådanne produktet samt anden dermed i forbindelse stående virksomhed.
Address
Gdanskgade 18
Email
info@veloxis.com
Website
www.veloxis.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 45.335 | 0 | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 1.256.475 | -385 | -214 | -308 | -589 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 1.256.475 | -385 | -214 | -308 | -589 |
| Net financials | 1.236 | 3.009 | 34 | 28 | -268 |
| Profit before tax | 1.257.711 | 2.624 | -180 | -280 | -857 |
| Tax | 200.250 | 564 | -77 | 12.989 | -213 |
| Net profit | 1.057.461 | 2.060 | -103 | -13.269 | -644 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1.304.141 | 3.885 | 3.367 | 3.326 | 89.916 |
| Equity | 1.303.915 | 2.881 | 2.778 | -10.491 | 88.648 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 226 | 1.004 | 589 | 13.817 | 1.269 |
| Total debt | 226 | 1.004 | 589 | 13.817 | 1.269 |
EBITDA margin
-58900000.0%
This company
15.8%
Market median
-372784910% vs market
20212025
Equity ratio
98.6%
This company
38.2%
Market median
+158% vs market
20212025
Return on equity
-0.7%
This company
18.4%
Market median
-104% vs market
20212025
Net profit margin
-64400000.0%
This company
8.1%
Market median
-795061828% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
DM Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (17) | ||
KJ Management | Management | 2008 – 2009 |
ME Chief Executive Officer | Chief Executive Officer | 2021 – 2024 |
MW Management | Management | 2003 – 2008 |
TN Management | Management | 2002 – 2003 |
PG Management | Management | 2008 – 2012 |
AS Management | Management | 2016 – 2017 |
MM Management | Management | 2018 – 2018 |
FØ Chief Executive Officer | Chief Executive Officer | 2006 – 2008 |
JM Chief Executive Officer | Chief Executive Officer | 2003 – 2006 |
MB Management | Management | 2008 – 2008 |
WJ Chief Executive Officer | Chief Executive Officer | 2009 – 2015 |
CA Chief Executive Officer | Chief Executive Officer | 2015 – 2021 |
HC Management | Management | 2008 – 2008 |
ID Management | Management | 2018 – 2021 |
JS Management | Management | 2012 – 2016 |
JS Chief Executive Officer | Chief Executive Officer | 2008 – 2009 |
KS Management | Management | 2002 – 2002 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2023 | |
| Former (24) | ||
| Chairman | 2006 – 2009 | |
| Board of Directors | 2016 – 2020 | |
| Chairman | 2009 – 2011 | |
| Deputy Chairman | 2016 – 2020 | |
| Board of Directors | 2002 – 2002 | |
| Chairman | 2002 – 2002 | |
| Board of Directors | 2008 – 2020 | |
| Chairman | 2011 – 2015 | |
| Board of Directors | 2011 – 2013 | |
| Board of Directors | 2005 – 2011 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2005 – 2011 | |
| Deputy Chairman | 2009 – 2016 | |
| Board of Directors | 2016 – 2020 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2002 – 2006 | |
| Board of Directors | 2021 – 2022 | |
| Board of Directors | 2002 – 2005 | |
| Chairman | 2021 – 2023 | |
| Board of Directors | 2002 – 2005 | |
| Chairman | 2016 – 2020 | |
| Board of Directors | 2016 – 2020 | |
| Chairman | 2020 – 2021 | |
| Board of Directors | 2006 – 2013 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2021 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2012 | |
| Company | 100% | 100% | 2020 | |
| Company | 33.33–49.99% | 33.33–49.99% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VELOXIS PHARMACEUTICALS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Jexner Hamberg | Management | 0 companies |
| Mark Earl Hensley | Chief Executive Officer | 0 companies |
| Michael Wolff Jensen | Management | 0 companies |
| Tomas Norling | Management | 0 companies |
| Peter Gudmund Nielsen | Management | 0 companies |
| Alastair Stuart McEwan | Management | 0 companies |
| Morten Marott | Management | 0 companies |
| Flemming Ørnskov | Chief Executive Officer | 0 companies |
| Jan Møller Mikkelsen | Chief Executive Officer | 0 companies |
| Michael Beckert | Management | 0 companies |
| William James Polvino | Chief Executive Officer | 0 companies |
| Craig Alexander Collard | Chief Executive Officer | 0 companies |
| Hans Christian Eberhard Groth Teisen | Management | 0 companies |
| Ira Duarte | Management | 0 companies |
| Daisuke Matsuo | Chief Executive Officer | 0 companies |
| Johnny Stilou | Management | 0 companies |
| James Stewart New | Chief Executive Officer | 0 companies |
| Klaus Søgaard | Management | 0 companies |
| Claus Tycho Bræstrup | Chairman | 0 companies |
| Robert Samuel Radie | Board of Directors | 0 companies |
| Paul Edick | Chairman | 0 companies |
| Mette Kirstine Agger | Deputy Chairman | 0 companies |
| Troels Elkiær Andersen | Board of Directors | 0 companies |
| Jan-Erik Gunnar Svensson | Chairman | 0 companies |
| Anders Götzsche | Board of Directors | 0 companies |
| Kim Bjørnstrup | Chairman | 0 companies |
| Edward Etienne Penhoet | Board of Directors | 0 companies |
| Gaston Georges Gerard Soula | Board of Directors | 0 companies |
| Yusuke Hiramatsu | Board of Directors | 0 companies |
| Jean Joachim Deleage | Board of Directors | 0 companies |
| Thomas Peter Dyrberg | Deputy Chairman | 0 companies |
| Kenro Yuzaki | Board of Directors | 0 companies |
| Lars Kåre Viksmoen | Board of Directors | 0 companies |
| Matthew Ryan Dumont | Board of Directors | 0 companies |
| Anders Buur | Board of Directors | 0 companies |
| Keigo Nakatsukasa | Chairman | 0 companies |
| Hiroki Ideguchi | Board of Directors | 0 companies |
| Florian Schønharting | Board of Directors | 0 companies |
| Hideo Hikami | Chairman | 0 companies |
| Ole Vahlgren | Board of Directors | 0 companies |
| Michael Thomas Heffernan | Chairman | 0 companies |
| Paul Kevin Wotton | Board of Directors | 0 companies |
| Masaya Etoh | Chairman | 0 companies |
| Kurt Anker Nielsen | Board of Directors | 0 companies |